Home

Vůle podložka Převzít events per 100 patient years Hrubý spánek Blesk Kalamita

Adverse Events Incidence Rates
Adverse Events Incidence Rates

Event rates per 100 patient-years follow-up (number of events) | Download  Table
Event rates per 100 patient-years follow-up (number of events) | Download Table

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with  Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years  of Exposure | SpringerLink
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure | SpringerLink

Cleveland Clinic Journal of Medicine : March 2023 - CD
Cleveland Clinic Journal of Medicine : March 2023 - CD

Event rate (per 100 patient-years) and risk of study endpoints... |  Download Scientific Diagram
Event rate (per 100 patient-years) and risk of study endpoints... | Download Scientific Diagram

Adverse events of special interest per 100 patient-years during the... |  Download Scientific Diagram
Adverse events of special interest per 100 patient-years during the... | Download Scientific Diagram

Event rates per 100 patient-years at 3 years for important vascular... |  Download Scientific Diagram
Event rates per 100 patient-years at 3 years for important vascular... | Download Scientific Diagram

Event rate per 100 patient-years of adverse clinical events for each... |  Download Scientific Diagram
Event rate per 100 patient-years of adverse clinical events for each... | Download Scientific Diagram

ncidence of severe hypoglycemic episodes per 100 patient-years in... |  Download Scientific Diagram
ncidence of severe hypoglycemic episodes per 100 patient-years in... | Download Scientific Diagram

Cleveland Clinic Journal of Medicine : September 2021 - CD
Cleveland Clinic Journal of Medicine : September 2021 - CD

Treatment-emergent adverse events per 100 patient-years by years of... |  Download Scientific Diagram
Treatment-emergent adverse events per 100 patient-years by years of... | Download Scientific Diagram

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis |  NEJM
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis | NEJM

RA | Safety Data & Possible Side Effects | RITUXAN® (rituximab)
RA | Safety Data & Possible Side Effects | RITUXAN® (rituximab)

Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5  Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase  3 Clinical Trial - ACR Meeting Abstracts
Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial - ACR Meeting Abstracts

Adverse events of special interest per 100 patient-years during the... |  Download Scientific Diagram
Adverse events of special interest per 100 patient-years during the... | Download Scientific Diagram

Transcatheter Closure of Patent Foramen Ovale in Older Patients With  Cryptogenic Thromboembolic Events | Circulation: Cardiovascular  Interventions
Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events | Circulation: Cardiovascular Interventions

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis  with over 2 Years Median Time in Treatment | The Journal of Rheumatology
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment | The Journal of Rheumatology

Real-world safety and effectiveness of rivaroxaban using Japan-specific  dosage during long-term follow-up in patients with atrial fibrillation:  XAPASS | PLOS ONE
Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS | PLOS ONE

Primary end point in normotensive and hypertensive patients at baseline (events  per 100 patient-years of follow-up) Primary end point Nifedipine Placebo. -  ppt download
Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo. - ppt download

Incidence of serious adverse events per 100 patient-years in the UPLIFT...  | Download Table
Incidence of serious adverse events per 100 patient-years in the UPLIFT... | Download Table

Adalimumab trials show low rate of IBD adverse events
Adalimumab trials show low rate of IBD adverse events

Dupilumab reduces length, frequency of hospital stays for patients with  atopic dermatitis
Dupilumab reduces length, frequency of hospital stays for patients with atopic dermatitis

Adverse events per 100 patient-years of exposure | Download Scientific  Diagram
Adverse events per 100 patient-years of exposure | Download Scientific Diagram

exposure-adjusted Aes through week 52 (event rate per 100 patient-years) |  Download Table
exposure-adjusted Aes through week 52 (event rate per 100 patient-years) | Download Table

incidence rate (events/100 patient-years) of AE and ADR classifi ed by... |  Download Scientific Diagram
incidence rate (events/100 patient-years) of AE and ADR classifi ed by... | Download Scientific Diagram

Patient Years Multiplier:
Patient Years Multiplier:

Tezepelumab shows long-term safety, efficacy for severe asthma
Tezepelumab shows long-term safety, efficacy for severe asthma